Nivolumab Associated With Higher Survival in Pediatric Advanced-Stage Hodgkin Lymphoma

Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL).

Read more: https://www.roswellpark.org/newsroom/202312-nivolumab-associated-higher-progression-free-survival-pediatric-advanced-stage